Ascendis製藥 ASND 深 滬

Ascendis Pharma shares are trading lower after the company reported mixed Q1 financial results.

Ascendis Pharma shares are trading lower after the company reported mixed Q1 fi...

05-07 20:05

Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of $(1.66) per share from

05-07 19:56

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

04-30 20:01

Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares

An announcement from Ascendis Pharma ( ($ASND) ) is now available. On April 21,...

04-21 21:51

美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价

今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元

04-17 11:27

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $292

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $262 to $292.

04-16 22:12

美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价

今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元

04-10 18:27

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $273 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $273 price target.

04-09 21:01

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

04-08 16:00

Ascendis Pharma's YUVIWEL Granted FDA's Orphan Drug Designation To Treat Linear Growth In Children

Ascendis Pharma A/S (NASDAQ:ASND) today announced that YUVIWEL (navepegritide; developed as TransCon® CNP) was granted orphan drug exclusivity by the U.S. Food & Drug Administration (FDA) and that YUVIWEL is now

04-07 04:03